The Oncology Research Internship (ORI) is a unique opportunity for participants to learn about oncology research from our team of Oncology Research Professionals.

Five (5) Oncology Research Interns will be selected from applications received. Limiting Internship to five candidates will provide a learning experience that is up-close and personal.

WHO CAN APPLY?

1) High School Seniors: Class of 2017 or 2018
2) First year college students who would like to obtain basic knowledge about cancer, cancer treatment and the research process are welcome to apply.

WHAT ARE THE DATES FOR THE INTERNSHIP? ORI will begin on June 19 and will end on July 14 (4 weeks in length). An average day during the ORI will be 5—8 hours in length.

PROGRAM REQUIREMENTS

❖ Parental / Guardian Permission
❖ Good academic standing & Satisfactory conduct/grades
❖ Proof of medical insurance coverage
❖ A video submission or written essay explaining why the applicant would like to be an Oncology Research Intern participant
❖ Letter of Recommendation from a previous teacher
❖ Students are responsible for transportation to and from CTRC, UTHSCSA
❖ Out of town candidates are responsible for housing

See reverse for additional requirements

The IDD® Oncology Research Internship (ORI) will provide selected candidates with an up-close and personal view of the drug development process. Initially interns will work closely with staff in each of our CTRC research departments this will provide basic information of what takes place in each department; after learning about each of our research areas and their role in drug development the intern will be assigned a mentor in an area they will like to learn more about.

Participating CTRC Departments

Clinical Trials Office - (CTO): The administrative aspect of clinical trial conduct begins in the Clinical Trials Office. The CTO Staff negotiate Study Budgets, contracts and grants.

Regulatory Affairs
There are many rules and regulations that Research Centers are bound to - human research protection (safety) is of utmost importance—Regulatory Affairs maintains official study documents / files

Research Infusion Room
The staff in the Research Infusion Room are responsible for the administration of experimental treatments to cancer patients who have exhausted conventional means of treatment. The nurses who work here are specially trained to care for cancer patients with advanced disease.

Department of Clinical Investigations (DCI)
Responsible for screening potential candidates for assigned studies; monitoring active patients; reporting side effects to sponsors and educating staff.

Pharmacokinetic Sampling Department
How long does an experimental drug stay in the body? When does it peak? Does taking experimental drug with or without food have an effect on its concentration in the blood? How is the drug excreted from the body? Answers to these questions and many others are obtained through the evaluation of the work performed in the PK Sampling Department.

For more information please contact:
Rachel Ortiz-Wong, Project Coordinator
CTRC - Institute for Drug Development
Phone: (210) 450-5055
Email: wongro@uthscsa.edu
PROGR A M  R E Q U I R E M E N T S
(continued)
For security and safety reasons it is the University’s decision that visiting individuals establish legitimacy on campus and receives all necessary training and testing to assure their own and the University’s patients safety. Thus, the program has a new protocol for participation.

Confidentiality /Security Acknowledgment

APPLICATION PROCESS
Application form will be provided for completion. There is a step I, II & III process where applicable. There is a $25.00 processing fee. A background check form will need to be completed.

OTHER FEES
Obtaining University Badge ($10 charge)
Parking Permit (cost of parking permit varies based on location)

Application Deadline
March 3, 2017

CTRC Institute for Drug Development®
Seeking Cures & Patients for Phase I, II & III Clinical Trials

The CTRC’s Institute for Drug Development (IDD®), pushes the frontier of cancer research to develop novel cancer treatments through partnerships with the NCI and with pharmaceutical and biotechnology companies. The IDD® accelerates the development of anticancer agents by integrating basic, translational and clinical research on the UT Health Science Center campus with CTRC clinicians. Many hundreds of anticancer agents have been tested here and many of the most important and effective cancer drugs currently in use today were either developed or first tested at IDD®.

Patients receive the standard of care and they have access to the latest treatments available. CTRC faculty specialize in different tumor types and use their expertise to choose the best option for each patient.

Each year, more than 350 patients from around the world come to the CTRC to participate in clinical trials and receive treatment with new drugs. At any given time, the CTRC is testing as many as 60 new drugs.

The IDD® is home to one of the world’s largest Phase I clinical studies programs for evaluating new cancer drugs. Phase I clinical studies are the first time that a new compound is used in patients, the initial step toward approval from the Food & Drug Administration. These studies establish the safety and appropriate dosage of new cancer drugs. The CTRC also conducts Phase II and Phase III trials which continue to evaluate a drug’s safety, effectiveness and to compare it with current standard of care.

The IDD® is funded by grants from the NCI and the Department of Defense, other public agencies and private foundations, industry contracts, clinical practice, philanthropy and investments.

Program Coordinators

S. Lisa Creighton, BS, CCRP
Regulatory Affairs Manager
210-450-1366 | creighton@uthscsa.edu

Rachel Ortiz-Wong
Project Coordinator
210-450-5055 | wongro@uthscsa.edu

For more Information please contact:
Rachel Ortiz-Wong, Project Coordinator
CTRC- Institute for Drug Development
Phone: (210) 450-5055
Email: wongro@uthscsa.edu